tricolor (Castellanos-Arvalo et al., 2020
The goal is to make prescription weight loss accessible without removing the clinical oversight that these medications require
To the best of our knowledge, there are no clinical studies that have examined the potential of CGRP receptor antagonists in clinical populations of asthmatics
Emerging studies are exploring whether GLP-1s could also help slow the progression of kidney disease, though current findings are still preliminary
The most frequently reported adverse events (AEs) of GLP-1 RAs were gastrointestinal adverse drug reactions, including nausea, vomiting, and abdominal pain, which were closely related to activation of central and peripheral GLP-1 receptors ( In a recent network meta-analysis, overall GLP-1 RAs significantly increased the incidence of gastrointestinal AEs compared with placebo or conventional treatment, and the odds ratios for nausea, vomiting and diarrhea from GLP-1 RAs were 11.8 (95% CI, 2.8946.9), 51.7 (95% CI, 7.07415), and 4.93 (95% CI, 1.7514.7), respectively (1214)